TRVI
Trevi Therapeutics Inc.
$8.55
+$0.40(+4.91%)
63
Overall
--
Value
63
Tech
--
Quality
Market Cap
$992.48M
Volume
1.46M
52W Range
$2.36 - $9.92
Target Price
$20.36
Order:
Income Statement
| Metric | Trend | Chart | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|
| OPERATING EXPENSES | ||||||||
| Operating Expenses | $26.6M | $32.5M | $32.5M | $29.9M | $33.9M | $51.5M | ||
| Research & Development | $19.3M | $22.3M | $23.0M | $19.8M | $23.7M | $39.4M | ||
| Research Expense | $19.3M | $22.3M | $23.0M | $19.8M | $23.7M | $39.4M | ||
| Selling, General & Administrative | $7.3M | $10.2M | $9.5M | $10.1M | $10.2M | $12.1M | ||
| General & Administrative Expenses | $7.3M | $10.2M | $9.5M | $10.1M | $10.2M | $12.1M | ||
| Salaries & Wages | $-1.1M | $2.4M | $2.5M | $2.3M | $2.2M | $3.6M | ||
| Depreciation & Amortization | $-39.0K | $47.0K | $50.0K | $43.0K | $81.0K | $94.0K | ||
| Depreciation & Amortization | $-39.0K | $47.0K | $50.0K | $43.0K | $81.0K | $94.0K | ||
| Other Operating Expenses | -- | -- | -- | $123.0K | $323.0K | $389.0K | ||
| OPERATING INCOME | ||||||||
| Operating income | $-26.6M | $-32.5M | $-32.5M | $-29.9M | $-33.9M | $-51.5M | ||
| EBITDA | $-26.0M | $-32.3M | $-32.7M | $-28.0M | $-28.4M | $-47.3M | ||
| NON-OPERATING ITEMS | ||||||||
| Interest Expense (Non-Operating) | -- | $456.0K | $1.2M | $1.2M | $391.0K | -- | ||
| Intinc | $577.0K | $178.0K | $10.0K | $1.7M | $4.7M | $3.6M | ||
| Net Non-Operating Interest Income/Expense | $577.0K | $-278.0K | $-1.2M | $577.0K | $4.7M | $3.6M | ||
| Gain on Sale of Securities | -- | $-9.0K | $82.0K | $-147.0K | -- | -- | ||
| Other Income/Expense | -- | $9.0K | $293.0K | $142.0K | $-469.0K | $15.0K | ||
| Other Special Charges | -- | $-9.0K | $-375.0K | $289.0K | $469.0K | $-15.0K | ||
| PRE-TAX INCOME | ||||||||
| EBIT | $-26.1M | $-32.3M | $-32.8M | $-28.0M | $-29.1M | $-47.9M | ||
| Pre-Tax Income | $-26.1M | $-32.8M | $-34.0M | $-29.2M | $-29.1M | $-47.9M | ||
| INCOME TAX | ||||||||
| Tax Provision | $-18.0K | $-18.0K | $-21.0K | $-36.0K | $-32.0K | $-30.0K | ||
| NET INCOME | ||||||||
| Net Income | $-26.1M | $-32.8M | $-33.9M | $-29.2M | $-29.1M | $-47.9M | ||
| Net Income (Continuing Operations) | $-26.1M | $-32.8M | $-33.9M | $-29.2M | $-29.1M | $-47.9M | ||
| Net Income (Discontinued Operations) | $-26.1M | $-32.8M | $-33.9M | $-29.2M | $-29.1M | $-47.9M | ||
| Net Income (Common Stockholders) | $-26.8M | $-32.8M | $-33.9M | $-29.2M | $-29.1M | $-47.9M | ||
| Normalized Income | -- | -- | $-34.0M | -- | -- | $-48.0M | ||
| TOTALS | ||||||||
| Total Expenses | $26.6M | $32.5M | $32.5M | $29.9M | $33.9M | $51.5M | ||
| SHARE & EPS DATA | ||||||||
| Average Shares Outstanding | $11.7M | $18.1M | $22.8M | $64.5M | $99.0M | $102.0M | ||
| Average Shares Outstanding (Diluted) | $11.7M | $18.1M | -- | $64.5M | $99.0M | $102.0M | ||
| Shares Outstanding | $17.8M | $19.9M | $30.8M | $60.0M | $121.8M | $96.7M | ||
| Basic EPS | -- | $-1.81 | $-1.49 | $-0.45 | $-0.29 | $-0.47 | ||
| Basic EPS (Continuing Operations) | -- | $-1.81 | $-1.49 | $-0.45 | $-0.29 | $-0.47 | ||
| Diluted EPS | $-2.28 | $-1.81 | $-1.49 | $-0.45 | $-0.29 | $-0.47 | ||
| Diluted EPS (Continuing Operations) | $-2.28 | -- | -- | $-0.45 | $-0.29 | $-0.47 | ||
| OTHER METRICS | ||||||||
| Accretion On Preferred Stock | $-1.5M | -- | -- | -- | -- | -- | ||
| Accrued Preferred Stock Dividends | $2.2M | -- | -- | -- | -- | -- | ||
| Other Gand A | $7.3M | $10.2M | $9.5M | $10.1M | $10.2M | $12.1M | ||
| Otherunder Preferred Stock Dividend | $704.0K | -- | -- | -- | -- | -- | ||
| Preferred Stock Dividends | $704.0K | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TRVI | $8.55 | +4.9% | 1.46M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |